US Army Medical Research Institute Partners with Recce Pharmaceuticals for Groundbreaking Research Collaboration
Recce Pharmaceuticals has entered a research agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential of Recce's synthetic compounds in treating bio-threat pathogens. The collaborative research will focus on Recce's experimental drugs, RECCE 327 and RECCE 529.